Nomura Maintains 'Neutral' Rating on Hansoh Pharmaceutical (03692.HK), Raises Target Price to HK$17.23

According to the Zhitong Finance APP, Nomura released a research report stating that it has raised the target price of Hansoh Pharma (03692) from HK$15.03 to HK$17.23, maintaining a "Neutral" rating. The revenue and profit forecasts for this year have been increased by 2.7% and 6.9%, respectively, and for next year by 6% and 0.7%, respectively, to reflect the performance of antibody-drug conjugates (ADCs) in the first half of the year, as well as the progress of Almonertinib meeting expectations, offsetting sales pressure from generic drugs. The bank estimates that the company's revenue and profit in the first half of the year will increase by 38.2% and 86.1% year-on-year, respectively.